DaVita (DVA)
(Delayed Data from NYSE)
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for December 30th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 30th.
Top Ranked Growth Stocks to Buy for December 27th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 27th
Rosy Outlook for Outpatient and Home Healthcare Industry
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and participation in APM.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Top Ranked Growth Stocks to Buy for December 24th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 24th
U.S. Consumer Spending Bolsters Economic Growth: 5 Picks
by Zacks Equity Research
U.S. Consumer spending rises in November and with consumer sentiments' higher in December, these five stocks are a good buy.
DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $73.75, moving +0.41% from the previous trading session.
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
5 Healthcare Stocks to Keep the Winning Streak Alive in 2020
by Sapna Bagaria
Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.
Top Ranked Growth Stocks to Buy for December 17th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 17th
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Why Is DaVita HealthCare (DVA) Up 2.9% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Option Care Health (BIOS) Surges: Stock Moves 7.3% Higher
by Zacks Equity Research
Option Care Health (BIOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Top Ranked Growth Stocks to Buy for December 5th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 5th:
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Samsung, Target and Davita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Samsung, Target and Davita
A Holiday-Shortened Global Week Ahead
by John Blank
This is going to be a short trading week in the USA. Chief Strategist John Blank doesn't see much in the way of market moving events. Here are Reuters' latest five world market themes, reordered into relative importance for equity traders.
The Zacks Analyst Blog Highlights: Amedisys, DaVita, Tenet and Hanger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, DaVita, Tenet and Hanger
The Zacks Analyst Blog Highlights: DaVita, Quanta Services, CRA International, NRG Energy and First American Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Quanta Services, CRA International, NRG Energy and First American Financial
4 Healthcare Stocks to Gain From Stellar Q3 Earnings
by Manaswita Ghosh Dutta
Prominent activities in the healthcare sector are pushing the sector ahead this quarter.
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd